« Zurück
Startseite /
Baricitinib (phosphate)

Baricitinib (phosphate)

ArtNr	HY-15315A-10mg
Hersteller	MedChem Express
CAS-Nr.	1187595-84-1
Menge	10 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 500 mg 50 mg 5 mg
Kategorie	Neuroscience Neural Lineage Markers Neuroinflammation Metabolism Diabetes Glucose Homeostasis Neural Transcription Factors Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.97
Citations	[1]Fridman JS, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010 May 1;184(9):5298-307.\|[2]Jabbari A, et al. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Feb 26;2(4):351-5. bioRxiv. 2020 Nov 6:2020.10.04.325415. Commun Biol. 2021 Jun 2;4(1):654. J Clin Invest. 2024 Oct 1;134(19):e176828. JHEP Rep. 2025 Nov 6. Research Square Preprint. 2020 Dec 11:rs.3.rs-119695. ACS Nano. 2024 Mar 19;18(11):8337-8349. Acta Pharmacol Sin. 2021 May;42(5):814-823. Adv Sci (Weinh). 2020 Sep 24;7(21):2002518. Adv Sci (Weinh). 2024 Dec 5:e2410360. Aging Cell. 2025 Oct 20:e70273. Ann Rheum Dis. 2025 Sep 25:S0003-4967(25)04383-3. bioRxiv. 2018 Feb. bioRxiv. 2020 Jun. bioRxiv. 2020 Mar. bioRxiv. 2024 Jul 12:2024.07.11.603146. bioRxiv. 2024 Jul 7:2024.07.04.601620. bioRxiv. 2025 April 12. bioRxiv. 2025 February 21. bioRxiv. 2025 Jul 29. bioRxiv. 2025 Jul 31. bioRxiv. 2025 Sep 10:2025.09.05.673576. bioRxiv. 2025 Sep 24. Br J Pharmacol. 2024 Dec;181(23):4804-4821. Cancer Res. 2021 Dec 15;81(24):6131-6141. Cell Death Dis. 2025 Jul 11;16(1):512. Cell. 2021 Apr 15;184(8):2167-2182.e22. Chemrxiv. 2023 Aug 3. Chemrxiv. Aug 11, 2021. Diabetologia. 2024 Jan;67(1):124-136. Drug Resist Updat. 2025 Jul:81:101224. Eur J Pharm Sci. 2024 Jul 4:106845. Heliyon. 2018 Nov 26;4(11):e00979. Immunol Res. 2025 Jun 26;73(1):99. Inflammation. 2021 Feb;44(1):206-216. Institute of Natural Medicine,University of Toyama, Japan. 2018, Nov. Int Immunopharmacol. 2022 Sep:110:109044. Int Immunopharmacol. 2024 Aug 9:140:112894. Int J Mol Sci. 2025 May 19;26(10):4849. Int J Obes (Lond). 2015 Nov;39(11):1607-18. J Allergy Clin Immunol. 2024 Apr;153(4):1125-1139. J Autoimmun. 2022 Feb;127:102793. J Clin Invest. 2021 Dec 15;131(24):e145501. J Dermatol Sci. 2024 Oct 22. J Exp Med. 2024 Mar 4;221(3):e20230683. J Immunol. 2013 Oct 1;191(7):3568-77. J Immunother Cancer. 2025 May 11;13(5):e010831. Karolinska Institutet. 2024 May 31. Mol Syst Biol. 2024 Jan;20(1):28-55. Mol Ther Nucleic Acids. 2025 Mar 5;36(2):102502. Nat Commun. 2023 Apr 24;14(1):2342. Pharmacol Rep. 2024 Oct;76(5):1079-1088. Phytomedicine. 2025 Nov 25:150:157605. Platelets. 2022 Apr 3;33(3):404-415. PLoS One. 2017 Jul 14;12(7):e0181126. Proc Natl Acad Sci U S A. 2025 Aug 19;122(33):e2514837122. Res Sq. 2024 Jul 16. Research Square Preprint. 2024 Mar 21. Rheumatology (Oxford). 2023 Aug 1;62(8):2908-2917. RSC Adv. 2018, 8, 21534-21540. Sci Adv. 2024 Mar 22;10(12):eadl0368. Sci Immunol. 2024 Jul 12;9(97):eadn0178. Sci Rep. 2022 May 12;12(1):7843. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Science. 2017 Dec 1;358(6367):eaan4368. Signal Transduct Target Ther. 2021 Apr 24;6(1):165. SSRN. 2025 Jul 30. Toxicol Sci. 2020 Aug 1;176(2):410-422. University of Greifswald. 2025.
Smiles	N#CCC1(N2N=CC(C3=C4C(NC=C4)=NC=N3)=C2)CN(S(=O)(CC)=O)C1.O=P(O)(O)O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY3009104 (phosphate),INCB028050 (phosphate)
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	JAK
Manufacturer - HS Code	H315, H319, H320
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	469.41
Product Description	Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable JAK1/JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, respectively.
Manufacturer - Research Area	Inflammation/Immunology
Solubility	DMSO : 250 mg/mL (ultrasonic)
Manufacturer - Pathway	Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Clinical information	Launched
Isoform	JAK1; JAK2; JAK3; Tyk2
UNSPSC Code	12352005
Precautionary	H315, H319, H320

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.